2022 is starting on a worrisome note; patience warranted
13/01/22 -"While the fundamental metrics (i.e. DCF and NAV) continue to point to healthy upside potential (taking into consideration the long-term virtues of Philips’ offerings), the near-term is fraught with ..."
Pages
69
Language
English
Published on
13/01/22
You may also be interested by these reports :
03/08/26
Our TP has been cut slightly, reflecting an update to the model (net debt, and updated market parameters), with no change to the operational ...
03/08/26
Smart glasses development continues to erode margins. We will take a more conservative view of the company and revise our long-term margin ...
02/08/26
DiaSorin’s Q2 profitability surpassed expectations. Despite weak respiratory sales and challenges in China, revenue grew by mid-single digits. All ...
31/07/26
Siemens Healthineers’ Q3 sales slightly missed expectations, though profitability met forecasts. The Precision Therapy and Imaging segments reported ...